Related Experiment Videos
Specific mediator-directed therapy for gastrointestinal diseases
1Division of Gastroenterology, University Hospital, Nottingham, UK.
European Journal of Gastroenterology & Hepatology
|February 12, 1998
Summary
New treatments targeting specific inflammatory mediators show promise for chronic bowel inflammation. While effective in animal models, human trial results are mixed, requiring further investigation for inflammatory bowel disease therapy.
Area of Science:
- Gastroenterology
- Immunology
- Pharmacology
Background:
- Chronic bowel inflammation involves elevated inflammatory mediators like cytokines and eicosanoids.
- Current treatments (aminosalicylates, corticosteroids) have side effects and variable efficacy for Crohn's disease and ulcerative colitis.
Purpose of the Study:
- To explore the potential of specific inflammatory mediator inhibitors as safer, more targeted therapies for chronic bowel inflammation.
- To evaluate the efficacy of novel therapeutic strategies in preclinical and clinical settings.
Main Methods:
- Review of existing literature on inflammatory mediators in chronic bowel inflammation.
- Analysis of data from animal models and early-stage human clinical trials of specific mediator inhibitors.
Main Results:
- Specific inhibitors have demonstrated efficacy in animal models of bowel inflammation.
- Early human clinical trials in inflammatory bowel disease have yielded inconsistent results.
Conclusions:
- Targeting specific inflammatory mediators represents a potential therapeutic avenue for chronic bowel inflammation.
- Further research is needed to determine if this strategy offers a viable alternative to current treatments in humans.